Calyxt, Inc. CLXT
We take great care to ensure that the data presented and summarized in this overview for Calyxt, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CLXT
Top Purchases
Top Sells
About CLXT
Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.
Insider Transactions at CLXT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 12
2024
|
Carlo Broos Interim CFO |
SELL
Open market or private sale
|
Direct |
4,647
-5.89%
|
$23,235
$5.3 P/Share
|
|
Nov 11
2024
|
Carlo Broos Interim CFO |
BUY
Grant, award, or other acquisition
|
Direct |
20,500
+20.64%
|
$102,500
$5.75 P/Share
|
|
Sep 18
2024
|
Rory B Riggs Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+6.75%
|
$1,000,000
$4.0 P/Share
|
|
Jul 15
2024
|
Gregory Francis William Gocal Chief Scientific Officer & EVP |
SELL
Open market or private sale
|
Direct |
2,000
-0.63%
|
$20,000
$10.01 P/Share
|
|
Jul 12
2024
|
Gregory Francis William Gocal Chief Scientific Officer & EVP |
SELL
Open market or private sale
|
Direct |
2,000
-0.63%
|
$20,000
$10.0 P/Share
|
|
Jun 27
2024
|
Gregory Francis William Gocal Chief Scientific Officer & EVP |
SELL
Open market or private sale
|
Direct |
2,000
-0.62%
|
$20,000
$10.0 P/Share
|
|
Jun 11
2024
|
Rory B Riggs Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
98,040
+2.97%
|
$980,400
$10.2 P/Share
|
|
May 30
2024
|
Gerhard Prante Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,072
+7.23%
|
-
|
|
Dec 29
2023
|
Rory B Riggs Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
1,500,000
+32.58%
|
-
|
|
Dec 29
2023
|
Rory B Riggs Chief Executive Officer |
SELL
Conversion of derivative security
|
Direct |
1,500,000
-52.32%
|
-
|
|
Dec 29
2023
|
Rory B Riggs Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
1,505,967
+34.44%
|
-
|
|
Dec 12
2023
|
Rory B Riggs Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
517,107
+24.17%
|
$5,171,070
$10.58 P/Share
|
|
Sep 27
2023
|
Rory B Riggs Chief Executive Officer |
SELL
Other acquisition or disposition
|
Indirect |
39,476
-3.45%
|
-
|
|
Jun 01
2023
|
Rory B Riggs Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+0.09%
|
$31,000
$31.5 P/Share
|
|
May 31
2023
|
Jonathan Finn > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
1,518,015
+25.39%
|
-
|
|
May 31
2023
|
Jonathan Finn > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
1,276,247
+19.87%
|
-
|
|
May 31
2023
|
Jonathan Finn > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
1,206
+50.0%
|
-
|
|
May 31
2023
|
William Koschak Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,333
+24.51%
|
-
|
|
May 31
2023
|
Debra H Frimerman General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
5,533
+22.76%
|
-
|
|
May 31
2023
|
Travis Frey Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,733
+23.12%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 375K shares |
|---|---|
| Conversion of derivative security | 1.5M shares |
| Other acquisition or disposition | 1.51M shares |
| Open market or private purchase | 517K shares |
| Conversion of derivative security | 1.5M shares |
|---|---|
| Open market or private sale | 10.6K shares |